Peptide Association

Insights

NewsBlog
Start free intake

Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

Daily Peptide News

Latest Peptide News & Research

Breaking research, regulatory updates, and industry developments in the world of peptide science. Updated daily.

Updated today at 6:00 AM UTC

ResearchHigh

Semaglutide to Reduce Calorie Intake Slows Aging in Female Mice, as Might be Expected

A new study examining semaglutide's effects on aging in female mice highlights a persistent methodological challenge: GLP-1 receptor agonists that suppress appetite and reduce calorie intake may simply replicate the well-documented lifespan-extending effects of caloric restriction rather than revealing novel mechanisms. Researchers caution that the strong metabolic signal of reduced nutrient availability tends to obscure any independent biological effects of GLP-1 receptor agonism, particularly in short-lived animal models. More rigorous study designs will be necessary to isolate whether semaglutide confers longevity benefits beyond those attributable to appetite suppression alone.

SemaglutideGLP-1
Fight AgingSeptember 9, 2026
5 min read
ResearchHigh

Comparing the Responsiveness of Epigenetic Aging Biomarkers

Researchers have conducted a comparative evaluation of DNA methylation biomarkers to determine how sensitively each responds to a range of longevity interventions. The findings carry implications for how scientists and clinicians select and interpret biological age measurements when assessing the efficacy of interventions, including peptide-based therapies targeting aging pathways. Standardizing the most responsive biomarkers could accelerate the validation of longevity compounds in future clinical research.

Lifespan.ioSeptember 9, 2026
5 min read
IndustryHigh

Telemedicine company offers GLP-1s for addiction

A telemedicine company has begun offering GLP-1 receptor agonists as a treatment approach for addiction, reflecting a growing body of interest in the broader therapeutic applications of this drug class beyond metabolic disease. The move signals expanding clinical use cases for GLP-1 agents in behavioral health contexts. This development comes as providers and researchers continue to explore the neurological mechanisms by which GLP-1 compounds may reduce addictive behaviors.

GLP-1Semaglutide
STAT NewsSeptember 9, 2026
4 min read
ResearchHigh

New GLP-1 Hair Loss Insights; Wegovy in Kids; Are Fitness Trackers Lying to Users?

A Mendelian randomization study published in the Journal of Investigative Dermatology suggests that men genetically predisposed to androgenetic alopecia face an elevated risk of hair loss when using GLP-1 receptor agonist drugs. Separately, Truveta data points to a 19 percent increase in GLP-1 prescribing among pediatric patients, reflecting the expanding use of agents such as semaglutide in younger populations. These findings raise important clinical considerations around patient selection and safety monitoring for this widely prescribed drug class.

GLP-1Semaglutide
MedPage TodaySeptember 8, 2026
5 min read
ResearchHigh

Asthma, COPD Attacks Down With GLP-1 Drugs in the Picture

Real-world data from U.K. patient records has linked GLP-1 receptor agonists to a meaningful reduction in exacerbation risk for both asthma and chronic obstructive pulmonary disease. The findings add to a growing body of evidence suggesting that GLP-1 drugs may confer significant anti-inflammatory benefits beyond their established metabolic effects. Researchers and clinicians are increasingly examining pulmonary outcomes as a secondary area of therapeutic interest for this drug class.

GLP-1
MedPage TodaySeptember 8, 2026
4 min read
ResearchMedium

The copper peptide trend has gone from creams to injections — ahead of the science

NPR examines the rapidly growing popularity of copper peptides, which have migrated from topical cosmetic formulations into injectable applications driven largely by social media trends. While some evidence supports topical use for skin repair and anti-aging effects, experts caution that injectable copper peptide use is outpacing the available clinical science. The piece raises important questions about consumer safety and the regulatory landscape surrounding peptide-based aesthetic therapies.

Copper PeptideGHK-Cu
NPR HealthSeptember 7, 2026
5 min read
LongevityHigh

Late-Life GLP-1 Treatment Increases Lifespan in Female Mice

A new preclinical study found that late-life administration of semaglutide increased median lifespan in female mice by more than 12 percent, with improvements across multiple health markers that appear to extend beyond simple caloric restriction. The results suggest GLP-1 receptor agonists may exert direct longevity-related mechanisms rather than acting solely through reduced food intake. Researchers view the findings as a compelling foundation for further investigation into GLP-1 therapies as potential geroprotective agents.

SemaglutideGLP-1
Lifespan.ioSeptember 8, 2026
4 min read
Clinical TrialsHigh

Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12

A clinical trial for Wegovy (semaglutide) has met its primary endpoint in children ages 6 to 12, marking a significant expansion of GLP-1 receptor agonist data into younger pediatric populations. The findings add to the growing body of evidence supporting semaglutide's efficacy across age groups and may inform future regulatory submissions for broader labeling. This development underscores the continued clinical momentum behind GLP-1 therapies beyond the adult obesity indication.

SemaglutideGLP-1
Endpoints NewsSeptember 8, 2026
4 min read
LongevityMedium

Fight Aging! Newsletter, September 6th 2026

The September 6th edition of the Fight Aging! newsletter covers developments relevant to longevity medicine, including analysis of aging clock data derived from existing clinical trial interventions and immune system signatures associated with near-term health outcomes. The newsletter serves as a curated digest for researchers, investors, and clinicians tracking progress in the aging science and longevity therapeutics space. Topics span mechanistic aging research that broadly informs peptide and regenerative therapy development.

Fight AgingSeptember 6, 2026
6 min read
ResearchHigh

The copper peptide trend has gone from creams to injections — ahead of the science

NPR Health examines the growing use of GHK-Cu, a copper-binding peptide promoted for skin rejuvenation, wound healing, and anti-aging effects, as its application has expanded from topical creams into injectable formulations. Experts note that clinical evidence supporting injectable use remains limited, raising safety and efficacy concerns among dermatologists and researchers. The report highlights a widening gap between consumer adoption driven by social media and the peer-reviewed science available to substantiate therapeutic claims.

GHK-Cu
NPR HealthSeptember 7, 2026
5 min read
IndustryHigh

Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & Lee

Menarini Group, one of Italy's largest family-owned pharmaceutical companies, has secured European commercialization rights to a GLP-1 receptor agonist developed by Chinese firm Gan and Lee Pharmaceuticals, marking a significant new entrant into the competitive European obesity market. The licensing deal signals continued global expansion of the GLP-1 therapeutic class beyond the dominant players currently holding market share. This move reflects growing pharmaceutical industry investment in peptide-based metabolic therapies across international markets.

GLP-1
Endpoints NewsSeptember 4, 2026
4 min read
ResearchHigh

GLP-1s May Be Taking Our Eyes Off the Real Obesity Problem

A MedPage Today analysis highlights growing expert concern that GLP-1 receptor agonists, while clinically effective for obesity and cardiometabolic disease, may be diverting attention from the structural and societal drivers of the obesity epidemic. Researcher Laura Schmidt, PhD, argues that an overreliance on pharmacological solutions risks neglecting upstream public health interventions. The commentary contributes to an important ongoing debate about the appropriate role of peptide-based therapies within a broader obesity treatment framework.

GLP-1
MedPage TodaySeptember 4, 2026
4 min read
ResearchHigh

GLP-1 Scripts Rising Faster Among Adults With Serious Mental Illness

An analysis of U.S. insurance claims data spanning 2018 to 2024 revealed that adults with serious mental illness received GLP-1 drug prescriptions at higher rates than those without such diagnoses who shared the same underlying GLP-1-indicating conditions. The findings highlight an evolving prescribing pattern with implications for how GLP-1 therapies are being applied across complex patient populations. Researchers and clinicians will need to evaluate whether current evidence sufficiently supports this level of utilization in individuals with serious mental illness.

GLP-1
MedPage TodaySeptember 3, 2026
4 min read
Clinical TrialsHigh

Off-Label GLP-1 Use Skyrockets in Young Kids

A large cross-sectional analysis found that GLP-1 receptor agonist prescriptions for children ages 8 to 11 with obesity surged 310-fold since 2019, despite the absence of FDA approval for this age group. The findings raise significant questions about prescribing practices, safety data, and the regulatory boundaries governing GLP-1 therapies in pediatric populations. This trend is expected to draw increased scrutiny from clinicians, payers, and regulators focused on evidence-based use of these agents.

GLP-1
MedPage TodaySeptember 4, 2026
4 min read
RegulatoryCritical

Mounjaro's Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib

The FDA has expanded the approved indication for tirzepatide (Mounjaro) to include reduction of major adverse cardiovascular events in high-risk adults with type 2 diabetes, a significant label update announced by Eli Lilly. This expanded cardiovascular indication reinforces tirzepatide's growing clinical profile beyond glycemic control and weight management. The development is expected to broaden prescribing patterns and further drive market growth for the dual GLP-1 and GIP receptor agonist.

TirzepatideGLP-1GIP
MedPage TodaySeptember 1, 2026
4 min read
IndustryHigh

As GLP-1 Use Expands Into Dermatology, So Do the Medicolegal Implications

A medicolegal review published in MedPage Today highlights the emerging liability landscape as GLP-1 receptor agonists see increasing off-label use in dermatological practice. While formal legal cases remain infrequent, the review draws on LexisNexis legal data to caution practitioners about evolving risk exposure. Providers integrating GLP-1 therapies into dermatology workflows are advised to monitor this area closely as clinical adoption accelerates.

GLP-1
MedPage TodaySeptember 1, 2026
4 min read
LongevityMedium

What Can Be Learned About Aging Clocks from Existing Clinical Trial Data for Longevity Interventions?

This analysis examines how biological aging clocks, built using machine learning techniques applied to omics and clinical data, can be leveraged to evaluate longevity interventions within existing clinical trial datasets. A higher predicted clock age relative to chronological age correlates with elevated mortality risk and increased prevalence of age-related conditions across populations, making these tools valuable endpoints for assessing intervention efficacy. The piece explores the practical limitations and opportunities of applying aging clock methodologies to retrospective and prospective trial data.

Fight AgingAugust 31, 2026
5 min read
ResearchHigh

GLP-1 Studies Suggest Benefits Extend to Infectious Diseases

An international study of more than 7 million people with type 2 diabetes found that those taking GLP-1 receptor agonists were less likely to develop tuberculosis or to be hospitalized or die from infections. These results suggest that GLP-1 class therapies may confer immunomodulatory or anti-infective benefits that extend well beyond glycemic control and weight management. Researchers indicate that further investigation is warranted to understand the mechanisms underlying these associations.

GLP-1
MedPage TodayAugust 31, 2026
4 min read
Clinical TrialsHigh

GLP-1 Drugs Tied to Gallbladder and Biliary Risks in Youth

A retrospective analysis of TriNetX data involving over 37,000 adolescents and young adults found that GLP-1 receptor agonist use was associated with increased cumulative gallbladder and biliary events in younger populations. The findings raise important safety considerations for clinicians prescribing these agents to pediatric and young adult patients with overweight or obesity. This study adds to the growing body of evidence characterizing the risk profile of GLP-1 therapies beyond their established metabolic benefits.

GLP-1
MedPage TodayAugust 31, 2026
4 min read
IndustryHigh

STAT+: GLP-1 drugs are almost single-handedly forcing employers to reconsider workers' health care

The rapid adoption of GLP-1 receptor agonists is creating significant financial pressure on employer-sponsored health plans, prompting a broad reassessment of coverage strategies and benefit design across industries. As costs associated with these medications escalate, employers are confronting difficult decisions about formulary inclusion, prior authorization requirements, and long-term budget sustainability. This shift reflects the growing systemic influence of GLP-1 therapies beyond clinical settings and into the economics of workforce health management.

GLP-1
STAT NewsAugust 31, 2026
5 min read
IndustryHigh

Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify

Medicare has launched a pilot program offering GLP-1 receptor agonists to eligible seniors at a reduced cost of approximately $50 per month, representing a significant shift in access policy for this drug class. However, the program excludes many patients with serious underlying illnesses, raising concerns among clinicians and patient advocates about equitable access. The limitations of the pilot highlight ongoing policy tensions surrounding coverage expansion for GLP-1 therapies across the Medicare population.

GLP-1
NPR HealthAugust 30, 2026
4 min read
Clinical TrialsHigh

About a Quarter of Those Who Stop Wegovy Start Again

A large Danish cohort study of 157,822 first-time semaglutide initiators found that nearly half discontinued treatment within one year, raising important questions about long-term adherence to GLP-1 receptor agonist therapy for obesity. Approximately one quarter of those who stopped eventually restarted, suggesting a complex pattern of on-and-off engagement with semaglutide that has meaningful clinical and public health implications. The findings underscore the need for improved patient support strategies and shared decision-making frameworks around sustained GLP-1 therapy.

SemaglutideGLP-1
MedPage TodayAugust 28, 2026
4 min read
RegulatoryCritical

Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug

The FDA has approved Eli Lilly's tirzepatide (Mounjaro) for the reduction of major adverse cardiovascular events, marking a significant expansion of the GLP-1/GIP receptor agonist's approved indications beyond glycemic control and weight management. This approval strengthens tirzepatide's clinical profile and reinforces the cardiovascular benefit class established by GLP-1 receptor agonists. The decision is expected to have broad implications for prescribing patterns, payer coverage, and the competitive landscape among incretin-based therapies.

TirzepatideGLP-1GIP
Endpoints NewsAugust 28, 2026
4 min read
RegulatoryHigh

Impacts of CMS' GLP-1 pilot program begin to take shape

A federal CMS pilot program expanding access to GLP-1 weight loss medications for Medicare-eligible seniors is yielding early uptake data and reported patient benefits nearly two months after launch. The findings offer an initial look at how government-sponsored coverage of GLP-1 receptor agonists may reshape prescribing patterns and access among older populations. Analysts and providers are watching closely as the program's outcomes could influence broader Medicare drug coverage policy for this class of therapeutics.

GLP-1
Endpoints NewsAugust 27, 2026
5 min read
IndustryHigh

Lilly's move to hide Phase 1 pipeline draws mixed reviews

Eli Lilly, whose GLP-1 portfolio currently generates more revenue than any other drug franchise globally, has opted to cease public disclosure of its Phase 1 pipeline assets. The decision has drawn scrutiny from analysts and investors who view early-stage transparency as a signal of long-term innovation health. The move raises questions about competitive strategy in the increasingly crowded GLP-1 and incretin therapy landscape.

GLP-1Tirzepatide
Endpoints NewsAugust 27, 2026
4 min read
ResearchHigh

GLP-1s May Offer Benefit in Ulcerative Colitis, Real-World Data Suggest

A retrospective cohort study of 300 patients with ulcerative colitis found that use of GLP-1 receptor agonists, including liraglutide, was associated with improved remission rates. The real-world data add to a growing body of evidence suggesting anti-inflammatory and immunomodulatory effects of GLP-1 class therapies that extend beyond metabolic indications. These findings may prompt further investigation into the therapeutic role of GLP-1 receptor agonists in inflammatory bowel conditions.

GLP-1Liraglutide
MedPage TodayAugust 26, 2026
4 min read
Clinical TrialsHigh

GLP-1 Drugs Could Help Narrow Lifespan Gap in Serious Mental Illness

A large target trial emulation involving 195,184 propensity-score-matched adults found that initiating a GLP-1 receptor agonist was associated with significantly lower risks of all-cause mortality and cardiovascular events in patients with serious mental illness. The findings carry substantial implications for a population that historically faces a dramatically shortened lifespan compared to the general public. Researchers suggest GLP-1 therapies may represent a meaningful tool for addressing excess cardiometabolic mortality in this underserved group.

GLP-1
MedPage TodayAugust 26, 2026
5 min read
IndustryHigh

STAT+: Pharmalittle: We're reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more

A growing share of U.S. employers are moving to eliminate GLP-1 drug coverage, with approximately 14% having already dropped or planning to drop benefits by 2027 amid rising healthcare costs. This trend signals mounting pressure on patient access to GLP-1 receptor agonists such as semaglutide and tirzepatide outside of clinical settings. The shift has significant implications for the broader GLP-1 market and compounding pharmacy demand.

GLP-1SemaglutideTirzepatide
STAT NewsAugust 26, 2026
4 min read
LongevityMedium

This Overlooked Organ May Hold Answers to Longevity & Disease Risk

Emerging research is drawing attention to the thymus as a central regulator of immune function and a potentially significant factor in healthy aging and disease susceptibility. Scientists are investigating how thymic decline with age contributes to immunosenescence and overall longevity outcomes. Interest in thymus regeneration intersects with peptide therapy research, particularly peptides such as Thymosin Alpha-1 and TB-500 that are studied for their immunomodulatory properties.

Thymosin Alpha-1TB-500
MindBodyGreenAugust 24, 2026
4 min read
Clinical TrialsHigh

'Gray Market' Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings

A preprint study found that individuals using compounded 'gray market' retatrutide, an investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, achieved measurably less weight loss over up to 12 months compared to clinical trial participants. The findings raise important questions about the efficacy and consistency of compounded versions of unapproved investigational peptides circulating outside regulated trial settings. This research adds to growing scrutiny of compounded peptide products and their real-world performance relative to controlled study conditions.

RetatrutideGLP-1GIP
MedPage TodayAugust 25, 2026
5 min read
ResearchHigh

FDA Clears Novel Alzheimer's Blood Test

The FDA has cleared the PrecivityAD2 blood test, developed by C2N Diagnostics, for use in diagnosing Alzheimer's disease as part of a standard clinical workup. The test measures plasma amyloid beta and tau peptide ratios, marking a significant advance in noninvasive biomarker diagnostics. This clearance underscores the growing clinical relevance of peptide-based biomarkers in neurological disease detection.

amyloid betatau peptide
MedPage TodayAugust 21, 2026
4 min read
Clinical TrialsMedium

Sugary Drinks and Stomach Cancer; GLP-1 Use in IBD; Fiber Supplements for IBS

A randomized trial examining GLP-1 receptor agonist use in inflammatory bowel disease patients failed to support routine adoption of the therapy for that indication, adding important nuance to the expanding clinical applications of this drug class. The findings are part of a broader gastroenterology research roundup covering dietary risk factors and gastrointestinal interventions. Clinicians prescribing GLP-1 agents for off-label gastrointestinal conditions should note the trial's cautionary conclusions.

GLP-1
MedPage TodayAugust 20, 2026
4 min read
BreakthroughHigh

Ozempic does something unexpected to the brain's hunger neurons

New research in mice reveals that semaglutide activates hunger-linked neurons in the brain rather than suppressing them, challenging the prevailing scientific understanding of how the drug sustains fat loss. The counterintuitive finding suggests these neurons play an essential role in the weight-reduction mechanism of GLP-1 receptor agonists. Scientists believe the discovery could open new avenues for developing next-generation obesity therapeutics with improved efficacy.

SemaglutideGLP-1
ScienceDaily Sports MedAugust 20, 2026
4 min read
ResearchHigh

Using gray-market versions of Lilly's triple-G leads to relatively poor weight loss, study finds

A new study examining gray-market versions of Eli Lilly's retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, found that patients using these unauthorized alternatives experienced significantly inferior weight loss outcomes compared to those in clinical trials. Retatrutide has demonstrated weight loss of up to 25 percent in Phase 3 trials, making it one of the most promising obesity therapeutics in development. The findings raise serious concerns about the efficacy and safety of compounded or illicit versions of next-generation peptide-based obesity treatments.

RetatrutideGLP-1GIP
Endpoints NewsAugust 20, 2026
4 min read
IndustryHigh

Doc Imposter Sold GLP-1s; Fraudster Fugitive Nabbed; Plastic Surgeon's Lawsuits

A Chicago man faces federal charges after allegedly impersonating licensed physicians to obtain GLP-1 medications for paying clients without proper medical authorization, according to the Department of Justice. The case highlights growing enforcement action around unauthorized access to high-demand weight loss drugs. The prosecution underscores the legal and patient safety risks associated with circumventing legitimate prescribing channels for GLP-1 receptor agonists.

GLP-1
MedPage TodayAugust 20, 2026
4 min read
LongevityHigh

XPRIZE Healthspan Finalist Teams Announced

The XPRIZE Healthspan competition has announced its finalist teams, advancing efforts to rigorously benchmark interventions targeting the biology of aging. The initiative aims to fill a critical gap in longevity research by evaluating competing approaches against standardized functional metrics rather than relying solely on aging clocks, which remain unreliable for assessing novel mechanisms. The competition represents a structured push to identify which therapeutic strategies meaningfully improve healthspan beyond what lifestyle modifications alone can achieve.

Fight AgingAugust 19, 2026
4 min read
Clinical TrialsHigh

Amylin design debate heats up as Lilly's crucial mid-stage weight loss data near

The amylin receptor agonist class is emerging as a critical frontier in obesity pharmacology, with drug design decisions increasingly separating competitors in the space. Novo Nordisk's CagriSema, combining an amylin analog with a GLP-1 agonist, is anticipated to become the first approved therapy of its kind later in 2026, while Eli Lilly's mid-stage data are expected to further clarify whether molecular architecture drives meaningful clinical differentiation. The outcome of this design debate carries significant implications for next-generation weight loss pipelines beyond current GLP-1 monotherapy standards.

CagriSemaGLP-1CagrilintideSemaglutide
Endpoints NewsAugust 19, 2026
5 min read
Clinical TrialsHigh

GLP-1s and Birth Control; Retatrutide Lawsuits; Air Pollution and Menopause

Experts have raised concerns that GLP-1 receptor agonists may reduce the effectiveness of oral contraceptives, adding a new consideration for clinicians prescribing these widely used therapies. Separately, a phase III trial of avexitide, a first-in-class GLP-1 receptor antagonist, met its primary endpoint, and legal proceedings involving retatrutide have drawn attention to the competitive and regulatory landscape surrounding next-generation weight loss compounds. These developments collectively underscore the rapidly evolving clinical and legal environment surrounding GLP-1 class therapies.

GLP-1AvexitideRetatrutide
MedPage TodayAugust 18, 2026
5 min read
RegulatoryCritical

Watchdog Urges HHS to Investigate Conflicts Among FDA's Peptide Panelists

A consumer watchdog group has formally requested that the HHS Office of Inspector General investigate potential conflicts of interest among members of an FDA advisory committee that recommended adding six peptides to the agency's list of restricted compounds. The demand raises significant questions about the integrity of the advisory process that directly shapes which peptides remain accessible through compounding pharmacies. The outcome of this inquiry could have substantial regulatory implications for providers and patients who rely on compounded peptide therapies.

MedPage TodayAugust 18, 2026
4 min read
IndustryHigh

Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger

Eli Lilly, a dominant force in the GLP-1 therapeutics market, has entered a collaboration and licensing agreement with OmniAb valued at up to $370 million, targeting ion channel biology. The deal reflects continued aggressive investment by major GLP-1 developers to expand their discovery pipelines and platform capabilities. The partnership signals sustained industry momentum around next-generation approaches that complement or extend existing GLP-1 franchises.

GLP-1Tirzepatide
Endpoints NewsAugust 17, 2026
4 min read
Clinical TrialsHigh

STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

Colorado biotech Enveda has released preliminary Phase 1 data on a novel compound intended to help patients sustain weight loss and preserve muscle mass following GLP-1 receptor agonist therapy. The drug targets pathways associated with exercise adaptation, addressing a key clinical concern around muscle loss that accompanies GLP-1 driven weight reduction. If validated in larger trials, such an agent could become an important adjunct therapy within the expanding GLP-1 treatment landscape.

GLP-1leptin
STAT NewsAugust 18, 2026
5 min read
Clinical TrialsHigh

Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia

Amylyx Pharmaceuticals has announced a successful Phase 3 trial for avexitide, a GLP-1 receptor antagonist targeting post-bariatric hypoglycemia, marking a significant pivot for the company following its prior ALS research program. The positive readout positions avexitide as a potential first-in-class treatment for a condition that affects a meaningful subset of patients who have undergone bariatric surgery. This result underscores the growing therapeutic breadth of GLP-1 pathway modulation beyond weight loss and diabetes management.

avexitideGLP-1
Endpoints NewsAugust 18, 2026
4 min read
BreakthroughHigh

Scientists solve the mystery of a brain "switch" that can trigger weight loss in opposite ways

New research has revealed that the GIP receptor can promote weight loss through two distinct and seemingly contradictory mechanisms depending on its location in the brain. Activating the receptor in the brainstem suppresses appetite, while blocking it in the hypothalamus removes an inhibitory brake on satiety signaling. The findings suggest that combining GIP-targeting therapies with GLP-1 receptor agonists such as semaglutide could yield meaningfully stronger outcomes in obesity treatment.

GLP-1GIPSemaglutideTirzepatide
ScienceDaily Sports MedAugust 15, 2026
4 min read
Clinical TrialsHigh

Preoperative GLP-1s Don't Diminish Bariatric Surgery Results, Study Suggests

A retrospective review of 383 bariatric surgery patients found that preoperative use of GLP-1 receptor agonists did not reduce one-year weight loss outcomes compared to patients with no prior GLP-1 exposure. The findings carry meaningful implications for clinical protocols governing the sequencing of pharmacological and surgical obesity interventions. As GLP-1 medications continue to gain widespread adoption, understanding their interaction with bariatric procedures becomes increasingly important for both prescribers and surgical teams.

GLP-1SemaglutideTirzepatide
MedPage TodayAugust 13, 2026
4 min read
IndustryHigh

STAT+: Eli Lilly targets booming black market for retatrutide

Eli Lilly is taking aim at an expanding black market for retatrutide, a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors that remains under clinical investigation. The emergence of illicit channels for an unapproved compound raises significant concerns around patient safety, product quality, and intellectual property enforcement. The development underscores the widening gap between consumer demand for next-generation metabolic peptide therapies and the pace of regulatory approval.

RetatrutideGLP-1GIP
STAT NewsAugust 13, 2026
4 min read
IndustryHigh

STAT+: Pharmalittle: We're reading about Lilly 'black market' lawsuits, pushback over Trump vaccine plan, and more

Eli Lilly has filed six lawsuits against U.S. companies accused of illegally selling unauthorized versions of its experimental obesity drug retatrutide, a triple agonist peptide in late-stage development. The legal action underscores growing enforcement pressure around compounded and counterfeit versions of GLP-1 class therapies as major pharmaceutical manufacturers move to protect their pipelines. This development is significant for the compounding pharmacy and peptide therapy sectors, which have faced increasing scrutiny over the production and sale of unapproved analogues.

RetatrutideGLP-1
STAT NewsAugust 12, 2026
4 min read
IndustryHigh

GLP-1 Telehealth Platforms Rated by U.S. News

U.S. News and World Report has published its first-ever ratings of telehealth platforms offering GLP-1 weight-loss medications, evaluating 20 online providers dispensing FDA-approved brand-name therapies. The inaugural rankings introduce a new layer of consumer-facing accountability for a rapidly expanding digital prescribing market. The development reflects increasing scrutiny of how GLP-1 drugs are being accessed and distributed outside traditional clinical settings.

GLP-1SemaglutideTirzepatide
MedPage TodayAugust 12, 2026
3 min read
RegulatoryCritical

Eli Lilly files first lawsuits over retatrutide 'black market'

Eli Lilly has initiated legal action against six U.S. companies accused of illegally selling unauthorized versions of retatrutide, the company's investigational GIP, GLP-1, and glucagon receptor triple agonist still in clinical trials. The lawsuits mark the first enforcement litigation by Lilly targeting the illicit compounding and distribution of this pipeline obesity and diabetes drug. The case highlights growing pharmaceutical industry efforts to combat unauthorized peptide sales ahead of potential FDA approval.

RetatrutideGLP-1GIP
Endpoints NewsAugust 12, 2026
4 min read
ResearchHigh

Child Dies in Gene-Editing Trial; Wegovy & Dementia Score; RFK Jr. Questions Journal

New findings indicate that semaglutide, marketed as Wegovy, attenuated a proteomics-based dementia risk score, suggesting potential neuroprotective benefits beyond its established metabolic effects. This adds to a growing body of evidence that GLP-1 receptor agonists may have broad systemic applications beyond weight management and glycemic control. Researchers and clinicians are paying close attention as the therapeutic scope of semaglutide continues to expand across disease indications.

SemaglutideGLP-1
MedPage TodayAugust 11, 2026
4 min read
IndustryHigh

Deaths After GLP-1s; First Detransition Clinic for Youths; DXA Scans Decline

UK government regulators have reported more than 150 deaths possibly linked to injectable GLP-1 weight-loss medications, raising significant safety scrutiny around this class of drugs. The report underscores growing pharmacovigilance concerns as GLP-1 receptor agonists continue to see widespread adoption for obesity and metabolic conditions. Clinicians and regulators are being urged to monitor adverse event data closely as the safety profile of these agents is further evaluated.

GLP-1
MedPage TodayAugust 11, 2026
4 min read